The gene may be silenced — but has the drug actually delivered its intended pharmacological effect? Since patisiran became the first FDA-approved siRNA therapy in 2018, the field has expanded rapidly, with multiple siRNA drugs now approved across cardiometabolic, rare disease, and neuroscience indications. In cardiovascular space, inclisiran — a PCSK9-targeting siRNA licensed to Novartis — has demonstrated durable LDL-C reductions of approximately 50% in the Phase III ORION-10 and ORION-11 trials with twice-yearly dosing. More recently, next-generation Lp(a)-lowering siRNA candidates such as olpasiran (Amgen) and lepodisiran (Eli Lilly) have reported sustained Lp(a) reductions exceeding 90% in clinical studies. Yet a critical question looms larger than ever: once an siRNA successfully silences its target gene, how do we prove it has actually produced the expected pharmacological effect?

• When "mRNA Knockdown" Is No Longer the Endpoint

siRNA drugs work through RNA interference, mediating the degradation of target mRNA and thereby suppressing gene expression. Early in development, qPCR is the workhorse assay for gauging silencing efficiency. But here’s the catch: does a drop in mRNA always translate into a proportional drop in target protein? Not necessarily. Protein half-life, translational regulation, and tissue distribution can all create a disconnect between mRNA and protein levels. In other words, gene silencing is merely mechanistic evidence — it is the change in protein levels that more directly reflects the drug’s pharmacodynamic (PD) effect. This is precisely why biomarker detection has become an increasingly critical component of oligonucleotide drug development.

https://biologynotesonline.com/sirna-structure/

Figure 1. siRNA Mechanism of Action

• From mRNA to Protein: Did the Drug Actually Work?

A comprehensive PD evaluation framework for oligonucleotide therapeutics can be viewed as a continuum: target mRNA modulation → target protein changes → PD biomarker response → pharmacological effects. Using Inclisiran, a PCSK9-targeting siRNA therapeutic, as an example, the drug mediates PCSK9 mRNA degradation through the RNA interference (RNAi) pathway, thereby suppressing PCSK9 protein synthesis. In the ORION-10 and ORION-11 Phase 3 trials, circulating PCSK9 levels decreased, accompanied by an approximately 50% reduction in low-density lipoprotein cholesterol (LDL-C) levels. This evidence chain, linking target modulation to biomarker response, enables researchers to more clearly determine whether the drug’s mechanism of action translates into the intended biological effects. For siRNA therapeutics targeting lipid metabolism pathways, such as SAL0195, dynamic changes in disease-relevant biomarkers such as lipoprotein(a) [Lp(a)] can likewise provide important evidence of pharmacological activity.

Ultimately, oligonucleotide drug development needs to answer more than just: How much did the mRNA decrease? It also needs to address: How much did the target protein decrease? Did downstream biomarkers respond? And how durable was the pharmacological effect?

Figure 2. The PD Pathway of Oligonucleotide Therapeutics: From mRNA Modulation to Pharmacological Effects

• When Pharmacodynamic Evaluation Moves Beyond “Gene-Level” Readouts to Biomarker-Based Assessment

As oligonucleotide therapeutics advance into more extensive preclinical and clinical development, biomarkers are playing an increasingly important role in pharmacodynamic (PD) evaluation. They can help researchers:

• Confirm that target modulation translates into changes at the protein level. Quantitative ELISA measurement of target proteins such as PCSK9, ANGPTL3, and Activin E provides direct protein-level evidence to support PD assessment.
• Assess changes in disease-relevant biomarkers. Monitoring biomarkers such as lipoprotein(a) [Lp(a)] can provide further insight into how a therapeutic modulates relevant biological pathways.
• Characterize the magnitude and durability of pharmacological effects. Longitudinal biomarker analysis across different dose levels and time points can reveal response dynamics, supporting PD evaluation and dose exploration.
• Improve cross-species comparability of research data. For studies involving human, NHP, mouse, and other species, selecting assay systems with appropriate species reactivity can help generate more reliable and interpretable preclinical data.

Table 1. Pharmacodynamic (PD) Assessment Products

• Beyond Efficacy: Safety Biomarkers Matter Too

Oligonucleotide drug development is about more than demonstrating efficacy. Monitoring potential immune-related safety signals following treatment is equally important. For oligonucleotide therapeutics delivered using systems such as lipid nanoparticles (LNPs), complement activation represents an important potential safety concern. C3a, C5a, and soluble C5b-9 (sC5b-9) are established biomarkers for assessing complement activation and related immune responses. Longitudinal biomarker analysis across dose levels and time points can help characterize the magnitude and duration of these responses, identify potential safety signals, and generate data to inform subsequent development.

PD biomarkers help quantify pharmacological activity, while complement- and inflammation-related biomarkers provide critical insights into safety. Together, these biomarker assessments provide a more comprehensive framework for evaluating the efficacy, pharmacology, and safety of oligonucleotide therapeutics.

Table 2. Safety Assessment Products

In oligonucleotide drug development, biomarker analysis is about more than simply generating a numerical readout. It requires reliable quantitative results, robust assay performance, sufficient sensitivity, species-appropriate assay systems, and consistent data across different stages of development. From target proteins and PD biomarkers to complement and inflammatory factors, robust ELISA assays can translate molecular changes that are otherwise difficult to measure directly into quantifiable, comparable, and longitudinal data.

To support pharmacodynamic and safety assessment throughout oligonucleotide drug development, ACROBiosystems offers a broad portfolio of ELISA assays covering key biomarkers, supporting biomarker analysis across multiple development stages—from mechanism-of-action studies and preclinical PD assessment to safety evaluation.

• Verification Data
• Human Lipoprotein(a) [Lp(a)] ELISA Kit (Cat. No. CEA-B264)

Our ELISA Kit uses specific antibodies targeting non-KIV-2 epitopes. By designing the immunogen to avoid the highly polymorphic KIV-2 repeat region, we identified antibodies capable of providing consistent recognition across Apo(a) isoforms with different KIV-2 copy numbers. For real-sample evaluation, 43 healthy human serum samples were analyzed for Lp(a) concentrations. The measured Lp(a) levels across all 43 samples are shown below.

Table 3. Lp(a) Levels in 43 Healthy Human Serum Samples

• Human Activin E Dimer ELISA Kit（Cat. No. CEA-B247）

Activin E concentrations were evaluated in serum samples from healthy donors and donors with high body mass index (BMI). The assay achieved a 100% detection rate across all samples. The mean Activin E concentration was 12.78 ng/mL in healthy donors and 28.13 ng/mL in donors with high BMI.

Figure 4. Activin E Levels in Serum Samples from Healthy and High-BMI Donors

• Human PCSK9 ELISA Kit（Cat. No. CEA-C202）

Three high-PCSK9 samples were spiked into human serum and serially diluted at 1:2, 1:4, 1:8, and 1:16. PCSK9 concentrations were measured across the assay’s linear range to evaluate sample recovery. The mean recovery was 100.6% across the tested dilution ratios, demonstrating good dilutional linearity and recovery in serum samples.

Figure 5. Dilutional Linearity and Recovery of PCSK9 in Human Serum

• Human GDF-15 ELISA Kit (Cat. No. CEA-C077)

To evaluate the assay’s linearity, high-concentration GDF-15 was spiked into human serum to generate high-value samples, which were then serially diluted at 1:2, 1:4, 1:8, and 1:16. The mean recovery of GDF-15 was 109.23% across the tested serum samples.

Figure 6. Dilutional Linearity and Recovery of GDF-15 in Human Serum

Related Articles
>>Biomarkers: Enabling Precision Assessment of Cardio-Kidney-Metabolic (CKM) Syndrome

>>Autoimmune Disease 3.0: Biomarkers Driving the Future of Precision Drug Development